INTEGRATED BIOPHARMA INC
INBPDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
PEG-Interferon a-2b + Ribavirin
Chronic Hepatitis C Infection in HIV-Infected Persons
peginterferon alfa-2b (SCH 54031)
Hepatitis C, Chronic
temozolomide
Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PEG-Interferon a-2b + Ribavirin | Phase 3 | Chronic Hepatitis C Infection in HIV-Infected Persons | - | - |
peginterferon alfa-2b (SCH 54031) | Phase 3 | Hepatitis C, Chronic | - | - |
temozolomide | Phase 2 | Cancer | - | - |
Frequently asked questions
What is in INTEGRATED BIOPHARMA INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in INTEGRATED BIOPHARMA INC's (INBP) pipeline across Phase 3, Phase 2. Its lead program is PEG-Interferon a-2b + Ribavirin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is INTEGRATED BIOPHARMA INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for INTEGRATED BIOPHARMA INC (INBP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INBP biotech catalysts?→
Add INBP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow INTEGRATED BIOPHARMA INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.